KatherineK.MatthayMD

Professor of Pediatrics, UCSF

Overview of Dr. Matthay

Dr. Katherine Matthay is a hematologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Medical Center, UCSF Benioff Children's Hospital Oakland, and John Muir Medical Center, Walnut Creek. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 44 years. Dr. Matthay accepts several types of health insurance, listed below. She is one of 29 doctors at UCSF Medical Center and one of 3 doctors at John Muir Medical Center, Walnut Creek who specialize in Hematology. She has more than 100 publications and over 500 citings.

Office
505 Parnassus Ave
San Francisco, CA 94143
Book by Phone+1(877) 845-3058

Fax+1 415-502-4372

Education & Training

University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 1977 - 1978
University of ColoradoResidency, Pediatrics, 1973 - 1976
Perelman School of Medicine at the University of PennsylvaniaClass of 1973

Certifications & Licensure

CA State Medical License 1977 - 2025
CO State Medical License 1975 - 1983
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com

Clinical Trials

N99-02: Melphalan and Buthionine Sulfoximine Start of enrollment: 2001 Aug 01
Completed
Phase 1
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma Start of enrollment: 2000 May 01
Completed
Phase 1
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2004 May 01
Completed
Phase 1
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma Start of enrollment: 2008 Jun 01
Completed
Phase 2
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Start of enrollment: 2010 Oct 04
Active, not recruiting
Phase 1
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma Start of enrollment: 2010 Dec 01
Completed
Phase 1
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Available
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study Start of enrollment: 2013 Apr 09
Terminated
Early Phase 1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Start of enrollment: 2014 Jul 23
Terminated
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

128 citations
Advancing therapy for neuroblastoma.
Bo Qiu, Katherine K Matthay
Nature Reviews. Clinical Oncology. 2022-08-01
369 citations
Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group
Wendy B. London, Robert P. Castleberry, Katherine K. Matthay, A T Look, Robert C. Seeger
Journal of Clinical Oncology. 2005-09-20
133 citations
Opsoclonus‐myoclonus‐ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies—a report from the children's cancer group study
Emily F. Rudnick, Yasmin Khakoo, Nuno Lobo Antunes, Robert C. Seeger, Garrett M. Brodeur
Medical and Pediatric Oncology. 2001-06-01

Grant Support

Pediatric Malignancies ProgramNational Cancer Institute2007–2011
Clinical Therapy TrialsNational Cancer Institute2000–2011
NANT 2003-01: Phase I Study Of Oral Irinotecan, Temozolomide, And CefiximeNational Center For Research Resources2005
NANT #9902: Modulation Of L-PAM By BSO With Autologous Stem Cell SupportNational Center For Research Resources2005
Impact Of Body Composition On PK Of Doxorubin In Pediatric PatientsNational Center For Research Resources2005
Dose Escalation Study Of 131 I-MIBG With Chemotherapy And Stem Cell RescueNational Center For Research Resources2005
Anbl02p1: A Pilot Induction Regimen Incorporating Topotecan For NeuroblastomaNational Center For Research Resources2005
NANT 2001-03: Phase I Study Of CEP-701 In Patients With Refractory NeuroblastomaNational Center For Research Resources2004–2005
NANT 2001-01:A Phase I Investigation Of Il-12/Pulse IL-2 In ChildrenNational Center For Research Resources2004–2005
131 I-MIBG Double Infusion Followed By Stem Cells For Refractory NeuroblastomaNational Center For Research Resources2004–2005
131 I-Labeled MIBG For Treatment Of Advanced Neuroblastoma: A Phase II StudyNational Center For Research Resources2004–2005
Phase I Intergroup Trial Of Hu14.18-Il.2 Fusion Protein In ChildrenNational Center For Research Resources2004
Nant2002-01: A Phase I Study Of High Dose PyrazoloacridineNational Center For Research Resources2004
Impact Of Body Composition On PK Of Doxorubicin In PedNational Center For Research Resources2004
Advl0116: A Phase I Trial And PK Study Of R115777 In Pediatric PatientsNational Center For Research Resources2004
131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*National Cancer Institute2004
131imibg Escalating Dose Rapid Sequence Double InfusionNational Cancer Institute2003
CCG 09709: Fenretinide In Children W/ High Risk Solid TumorsNational Center For Research Resources2000–2002
CCG 0954: Gemcitabine In Solid TumorsNational Center For Research Resources2000–2002
Trial Of Temozolomide In Children And Adolescents With Progressive CancerNational Center For Research Resources1998–2002
Phase I Study Of Gamma Interferon Transduced Neuroblastoma CellsNational Center For Research Resources1998–2002
Phase I Study Of D1694 In Pediatric Patients With Advanced Neoplastic DiseaseNational Center For Research Resources1998–2002
Phase I Study Of Continuous 21 Day Topotecan In Children With Relapsed TumorsNational Center For Research Resources1998–2002
Phase I Study Of Anti B4 Blocked Ricin In Children With Leukemia Or LymphomaNational Center For Research Resources1998–2002
Pediatric Trial And PK Study Of Lgd1057National Center For Research Resources1998–2002
CI Mercaptopurine Followed By CI ARA-C In ChildrenNational Center For Research Resources1998–2002
B43-PAP Immunotoxin With 4 Drug Induction For All In RelapseNational Center For Research Resources1998–2002
Pilot Study Of Buthionine Sulfoximine In Combination With MelphalanNational Center For Research Resources1997–2002
I-131 MIBG Therapy For NeuroblastomaNational Center For Research Resources1997–2002
Phase I Study Of Taxotere In Pediatric Patients With Advanced Neoplastic DiseaseNational Center For Research Resources1996–2002
Phase I Chimeric Human/Murine Anti-Gd2 Monoclonal Antibody With GM-CSFNational Center For Research Resources1996–2002
Childrens Cancer GroupNational Cancer Institute1994–2002
Thrombopoietin &G-Csf In Child Solid TumorsNational Center For Research Resources2000
Paclitaxel In Refractory Leukemia In ChildrenNational Center For Research Resources2000
Phase I Study Of Topotecan And Field Radiation For Pontine Glioma Of ChildhoodNational Center For Research Resources1998–1999
Phase I Study Of Topotecan And Cisplatin In Solid Tumors In ChildrenNational Center For Research Resources1998–1999
Phase I Multiple Cycles Of High Dose Chemotherapy With Stem Cell TransfusionsNational Center For Research Resources1998–1999
IL 6 PLUS G-CSF Following ICE In Children With Recurrent Solid TumorsNational Center For Research Resources1998–1999
Phase I Study Of Taxol In Refractory Leukemia In ChildrenNational Center For Research Resources1997
Phase I Trial Of Temozolomide In Children &Adolescents With Progressive CancerNational Center For Research Resources1996
I-131 MIBG For Treatment Of Advanced NeuroblastomaNational Center For Research Resources1995–1996
Treatment Of Newly Diagnosed Acute Lymphoblastic Leukemia In ChildrenNational Center For Research Resources1995
Phase I Trial Of All-Trans Retinoic Acid In Combination With InterferonNational Center For Research Resources1995
Phase I Evaluation Of Oral/Intravenous Navelbine In Pediatric Cancer PatientsNational Center For Research Resources1995
Chemotherapy VS Autologous Bone Marrow Transplant For High Risk NeuroblastomaNational Center For Research Resources1995
Children'S Cancer Study GroupNational Cancer Institute1993
Treatment Of Leukemia By Antibody-Directed LiposomesNational Cancer Institute1989–1991
Treatment Of Bone Marrow By Antibody-Directed LiposomesNational Cancer Institute1985–1987

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PPO
Blue Shield California HMO
Blue Shield California PPO
First Health PPO
Health Net California Large Group PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment